PCSK9 Inhibitors: Exploring Treatment Options for Hyperlipidemia and Optimizing Patient Care
Regeneron Pharmaceuticals, Inc.
Faculty Presenter
Michael D. Moll, PharmD
Manager
Walgreens Community Based Specialty Pharmacy
Adjunct Clinical Professor of Pharmacy Practice
Fairleigh Dickinson University School of Pharmacy & Health Sciences
Adjunct Faculty Preceptor
Rutgers University Ernest Mario School of Pharmacy
New Brunswick, New Jersey
Medical Writer for Patient Counseling Script
Deep Patel, PharmD, MBA
Clinical Coordinator, Transitions of Care
Department of Pharmacy
Long Island Jewish Medical Center
New Hyde Park, New York
Program Description
In recent years, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as promising agents in the treatment of hyperlipidemia. Short-term and long-term studies for the 2 currently FDA-approved PCSK9 inhibitors have shown significant reduction in adverse cardiovascular events. Identifying patients with hyperlipidemia for whom PCSK9 inhibitors may be effective adjuvant therapy is just part of the pharmacist’s role; they must also be able to successfully educate patients on proper dosing and administration intervals to guarantee optimal adherence. Patient case videos are included in this webinar as the patient seeks instructions from the pharmacist regarding important counseling points and administration for a newly prescribed PCSK9 inhibitor.
Target Audience: Managed care and retail pharmacists
Type of Activity: Application
Release date: January 14, 2021
Expiration date: July 14, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the current FDA-approved PCSK9 inhibitors with clinical trial data on safety and efficacy and real-world data for the management of hyperlipidemia
- Express the mechanism of action, dosing, administration, and most common adverse effects of PCSK9 inhibitors
- Explore the role of the pharmacist in improving the outcomes of patients on PCSK9 inhibitors through an emphasis of motivational interviewing, medication education, and patient adherence
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-21-008-H01-P. The activity is available for CE credit through July 14, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Michael D. Moll, PharmD, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
